New Trials in Lupus and where Are we Going

New Trials in Lupus and where Are we Going Purpose of Review To review progress in the field of clinical trials for SLE. Recent Findings Treatment development for SLE has been marked by failures of many later phase studies, representing billions of dollars of lost research and development funding. Recently, more successful Phase II trials have tested reductions in back- ground medications, novel stringent endpoints, and identification of informative immunologic subsets to achieve greater treat- ment effects. A large number of agents with promising novel biologic mechanisms have continued to enter clinical development, and momentum is building to capitalize on newer strategies for trial designs. Summary Widespread SLE drug development is proceeding despite setbacks and controversies. Approaches focusing on pa- tients with high disease activity, reduction of background polypharmacy, or increased endpoint stringency provide strategies that might improve interpretation of trial results. Pharmacodynamics of immune-modulation is a field in its infancy, but ripe for development. . . . . Keywords Systemic lupus erythematosus Clinical trials Personalized medicine Interferon alpha Small molecules Introduction Targeting B Cells Despite a pressing need to develop more effective and less Because of their ubiquitous role in SLE pathogenesis [3], B toxic immune modulating therapies for systemic lupus cells have been a prime target http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Rheumatology Reports Springer Journals

New Trials in Lupus and where Are we Going

Loading next page...
 
/lp/springer_journal/new-trials-in-lupus-and-where-are-we-going-uLSS5Hmmnr
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Rheumatology
ISSN
1523-3774
eISSN
1534-6307
D.O.I.
10.1007/s11926-018-0745-1
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review To review progress in the field of clinical trials for SLE. Recent Findings Treatment development for SLE has been marked by failures of many later phase studies, representing billions of dollars of lost research and development funding. Recently, more successful Phase II trials have tested reductions in back- ground medications, novel stringent endpoints, and identification of informative immunologic subsets to achieve greater treat- ment effects. A large number of agents with promising novel biologic mechanisms have continued to enter clinical development, and momentum is building to capitalize on newer strategies for trial designs. Summary Widespread SLE drug development is proceeding despite setbacks and controversies. Approaches focusing on pa- tients with high disease activity, reduction of background polypharmacy, or increased endpoint stringency provide strategies that might improve interpretation of trial results. Pharmacodynamics of immune-modulation is a field in its infancy, but ripe for development. . . . . Keywords Systemic lupus erythematosus Clinical trials Personalized medicine Interferon alpha Small molecules Introduction Targeting B Cells Despite a pressing need to develop more effective and less Because of their ubiquitous role in SLE pathogenesis [3], B toxic immune modulating therapies for systemic lupus cells have been a prime target

Journal

Current Rheumatology ReportsSpringer Journals

Published: May 3, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off